The recent FDA Fast Track designation for BioRestorative Therapies' BRTX-100 program marks a significant milestone in the treatment of chronic lumbar disc disease (cLDD). Given the debilitating nature of cLDD and its prevalence among middle-aged Americans, this development has sparked considerable
Mirum Pharmaceuticals recently made headlines as they secured FDA approval for Ctexli, also known as chenodiol, as the first treatment for cerebrotendinous xanthomatosis (CTX). CTX, a rare genetic lipid storage disease, affects an estimated 3 to 5 individuals per 100,000. This approval came after a
The intersection of biotechnology and artificial intelligence (AI) is poised to address the inefficiencies and ethical concerns plaguing the current drug development process. One of the most promising innovations in this field is the Bio-AI clinical prediction platform developed by Quris-AI, which
In the midst of technological advancements, medical imaging tests like X-rays, MRIs, mammograms, and CT scans have become indispensable tools in modern diagnostics; however, questions about the safety and health risks associated with these tests frequently emerge. Radiation exposure is a common
Increasing incidences of bowel cancer are an alarming public health issue, so researchers have been examining dietary factors that might mitigate this risk. Recent research has indicated that calcium, a mineral predominantly found in dairy products, plays a protective role in preventing bowel
Sangamo Therapeutics, Inc., a leading genomic medicine company, has reported promising updated data from the Phase 1/2 STAAR study. This study explores the efficacy of isaralgagene civaparvovec (ST-920) as a treatment for Fabry disease. The analysis, which reflects data up to September 12, 2024,